Dihexa
Also known as PNB-0408, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, Hexanoyl-Tyr-Ile-Ahx-NH2, ATH-1001
A synthetic angiotensin IV analogue with no human study found. Its mechanism paper was retracted in 2025; FDA lists it as a withdrawn compounding nomination.
No human study of dihexa was found in PubMed, Europe PMC or ClinicalTrials.gov. The 2014 paper that proposed its mechanism, action through hepatocyte growth factor (HGF), was retracted in 2025 (source). The 2013 paper that first described dihexa carries a 2021 notice of concern (source). The stated reasons for both notices could not be read for this page. The widely quoted claim that dihexa is "seven orders of magnitude more powerful than BDNF" comes from a 2012 university press release about new connections between nerve cells in a dish, not memory, and not people (source).
What it is
Dihexa is described as an analogue of angiotensin IV. Its first description calls it an "orally active, blood-barrier permeant, metabolically stabilized analog" built on angiotensin IV's first three amino acids (source). It carries a hexanoyl cap and a 6-aminohexanoic amide, so it has no one-letter sequence. Its formula is C27H44N4O5 and its molecular weight 504.7 (source); FDA's substance registry classes it as a chemical rather than a protein (source).
PubChem lists ATH-1001 among dihexa's depositor-supplied synonyms (source). Athira's phase 1 paper describes fosgonimeton as "a water-soluble prodrug of ATH-1001" (source). Fosgonimeton is a different molecule, and its trials are not evidence about dihexa as sold.
Where the evidence comes from
The originating group, at Washington State University, reported that dihexa improved Morris water maze performance in rats with a scopolamine-induced deficit and in aged rats (source). That paper is under a notice of concern. Its mechanism paper is retracted and is not used here for any finding (source). M3 Biotechnology, a company co-founded by Joseph Harding, one of the 2013 paper's authors, part-funded a study in larval zebrafish where dihexa protected hair cells from acute antibiotic damage (source). A rat nerve-repair study with one of the group as co-author never gave dihexa alone, only with stem cells (source).
The BDNF comparison
BDNF, brain-derived neurotrophic factor, is a protein that supports nerve cell growth. The 2012 press release states that "it would take 10 million times as much BDNF to get as much new synapse formation as Dihexa", from "bench assays using living nerve cells" (source). No peer-reviewed abstract opened for this page contains that figure. A later paper citing the retracted mechanism study puts the difference at "seven times greater" (source). The two numbers disagree, and neither is primary data.
Safety and cancer questions
Because dihexa is proposed to act on the HGF and MET growth factor system, readers ask whether it could promote cancer. Searches of Europe PMC found no study that has examined this question for dihexa. That is an unstudied question, not a demonstrated risk, and not evidence of safety.
A market surveillance study by official medicines control laboratories detected dihexa once, in one laboratory, presented as a dietary supplement (source).
Regulatory position
FDA lists "Dihexa acetate" among bulk substances nominated for compounding but withdrawn (source). It is on the agenda of the Pharmacy Compounding Advisory Committee meeting FDA lists as to be scheduled before the end of February 2027, with no briefing published (source). A text search of the 503A list of 14 May 2026 found no entry (source). No FDA approval was found. Its status under anti-doping rules was not established from a primary document.
What the research shows
Each statement below is labelled with the strongest kind of study supporting it, and links to that study.
- Animal researchSupportive / Very low confidence
In Sprague-Dawley rats with a scopolamine-induced deficit and in aged rats, the group that first described dihexa reports improved performance in the Morris water maze; this 2013 paper carries a 2021 notice of concern.
McCoy and colleagues (2013) write that dihexa "exhibits excellent antidementia activity in the scopolamine and aged rat models and marked synaptogenic activity". A 2018 systematic review of animal studies, written before the notices, lists dihexa among analogues that "improved performance on spatial working memory and passive avoidance tasks".
Observed in animals. Animal results frequently fail to replicate in humans.
- Group sizes are not given in the abstract.
- The paper carries a 2021 notice of concern. The reasons could not be read for this page.
- Animal researchSupportive / Low confidence
In an independent study of male APP/PS1 mice, a model of Alzheimer's-type amyloid pathology, and wild-type C57 mice at six months old, with 6 animals per group (12 for some panels), dihexa is reported to restore performance in the Morris water maze.
Sun and colleagues (2021), a group in China, write: "Dihexa restored spatial learning and cognitive functions in the Morris water maze test."
Observed in animals. Animal results frequently fail to replicate in humans.
- Small groups: figures give 6 or 12 mice per group. The methods give inconsistent descriptions of how dihexa was given.
- The full text is not consistent on the probe trial: the Results say dihexa-treated mice "performed significantly better" for platform crossings, while the Figure 2 legend says dihexa "tended to increase" them.
- Animal researchSupportive / Low confidence
In an independent study of 33 male and 19 female Long-Evans rats with repeated closed-head mild traumatic brain injury, dihexa is reported to rescue working memory on a T-maze delayed non-match to position task, an effect blocked by a MET antagonist.
Martino and colleagues (2025), at Rowan University, report that dihexa "dose-dependently rescued working memory performance".
Observed in animals. Animal results frequently fail to replicate in humans.
- One rat study in one injury model.
- Animal researchNo effect found / Low confidence
In an independent study of 40 male Wistar rats given 3-nitropropionic acid (3-NP) to produce Huntington's disease-like symptoms over five weeks, dihexa did not protect against the deficits.
Wells and colleagues (2024) write: "PNB-0408 did not protect rats from the deficits induced by 3-NP neurotoxicity." PNB-0408 is another name for dihexa.
Observed in animals. Animal results frequently fail to replicate in humans.
- Only the abstract was read.
- Animal researchMixed / Low confidence
In larval zebrafish 5 to 6 days after fertilisation, with 5 to 11 larvae per group, dihexa protected lateral line hair cells from acute neomycin or gentamicin exposure, but not from chronic gentamicin or cisplatin.
Uribe and colleagues (2015) report protection that was "attenuated by co-treatment with the HGF antagonist 6-AH", and "no observed toxicity of Dihexa treatment alone" at the single concentration used.
Observed in animals. Animal results frequently fail to replicate in humans.
- Part-funded by M3 Biotechnology. The authors state that "Joseph W. Harding is co-founder and shareholder of M3 Biotechnology, Inc." and that Leen H. Kawas is its CEO; Harding is an author of the 2013 dihexa paper.
- Hair cells in fish larvae are not a hearing outcome in people.
- Animal researchInsufficient evidence / Very low confidence
In male Lewis rats with a cut and repaired sciatic nerve (6 to 8 per group), dihexa was only ever given together with stem cells, so the study cannot show any effect of dihexa itself.
Weiss and colleagues (2021) measured walking track analysis and a pain reaction test. Every group given dihexa also received mesenchymal stromal cells. One author is from dihexa's originating group.
Observed in animals. Animal results frequently fail to replicate in humans.
- Mechanistic reasoningInsufficient evidence / Very low confidence
The proposal that dihexa acts through hepatocyte growth factor (HGF) and its receptor MET rests on a 2014 paper retracted in 2025; two later studies report effects reduced by blocking HGF or MET.
Benoist and colleagues (2014) claimed that "dihexa binds with high affinity to hepatocyte growth factor (HGF)"; that paper is retracted. In zebrafish larvae an HGF antagonist weakened dihexa's protective effect, and in rats a MET antagonist blocked its effect on working memory.
A plausible biological explanation, not a measured outcome.
- The reason for the retraction could not be read for this page.
- Blocking an effect with an antagonist is indirect evidence; no independent binding study was found.
Reported and theoretical risks
- Mechanismunknown
No human safety data of any kind
FDA states that it "has not identified any human exposure data on drug products containing dihexa acetate" and that it "lacks important information regarding any safety issues raised by dihexa acetate," "including whether it would cause harm if administered to humans." Searches found no human study, case report or toxicology study.
Regulatory status
Status differs by country and changes over time. Each entry is dated and sourced.
USFDAnot approved
FDA lists "Dihexa acetate" in the table "Bulk drug substances nominated but withdrawn", stating: "FDA has not identified any human exposure data on drug products containing dihexa acetate" "administered via any route of administration." "FDA lacks important information regarding any safety issues raised by dihexa acetate," "including whether it would cause harm if administered to humans."
As of 22 April 2026. Source
USFDAunclear
"Dihexa acetate" is on the agenda of the Pharmacy Compounding Advisory Committee meeting FDA lists as to be scheduled before the end of February 2027, among substances being considered for inclusion on the 503A bulks list. No date, briefing document or outcome was published.
As of 15 April 2026. Source
USFDAunclear
A text search of FDA's 503A bulk drug substance categories list updated on 14 May 2026 found no entry for dihexa.
As of 14 May 2026. Source
Research and analysis
Sources
- 1. McCoy AT et al. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. The Journal of Pharmacology and Experimental Therapeutics. 2013. PubMed 23055539
- 2. Notice of Concern: McCoy AT, Benoist CC, Wright JW, et al. (2013) Evaluation of Metabolically Stabilized Angiotensin IV Analogs as Procognitive/Antidementia Agents. The Journal of Pharmacology and Experimental Therapeutics. 2021. PubMed 34551989
- 3. Ho JK, Nation DA. Cognitive benefits of angiotensin IV and angiotensin-(1-7): A systematic review of experimental studies. Neuroscience and Biobehavioral Reviews. 2018. PubMed 29733881(open access)
- 4. Sun X et al. AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway. Brain Sciences. 2021. PubMed 34827486(open access)
- 5. Martino KA et al. Hepatocyte Growth Factor/MET Activator Rescues Working Memory Deficits after Repeated Mild Traumatic Brain Injury. Neurotrauma Reports. 2025. PubMed 42825082(open access)
- 6. Wells RG et al. Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington's Disease-Like Symptoms in Rats. Journal of Huntington's Disease. 2024. PubMed 38489193
- 7. Uribe PM et al. Hepatocyte growth factor mimetic protects lateral line hair cells from aminoglycoside exposure. Frontiers in Cellular Neuroscience. 2015. PubMed 25674052(open access)
- 8. Weiss JB et al. Stem cell, Granulocyte-Colony Stimulating Factor and/or Dihexa to promote limb function recovery in a rat sciatic nerve damage-repair model: Experimental animal studies. Annals of Medicine and Surgery. 2021. PubMed 34703584(open access)
- 9. Benoist CC et al. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system (RETRACTED). The Journal of Pharmacology and Experimental Therapeutics. 2014. PubMed 25187433
- 10. Retraction notice to "The Procognitive and Synaptogenic Effects of Angiotensin IV-Derived Peptides Are Dependent on Activation of the Hepatocyte Growth Factor/c-Met System" [J Pharmacol Exp Ther 351 (2014) 390-402]. The Journal of Pharmacology and Experimental Therapeutics. 2025. PubMed 40312093
- 11. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. 2026. View source(open access)
- 12. Meeting of the Pharmacy Compounding Advisory Committee (to be scheduled before the end of February 2027). U.S. Food and Drug Administration. 2026. View source(open access)
- 13. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, updated May 14, 2026. U.S. Food and Drug Administration. 2026. View source(open access)